logo-loader

MaxCyte boss Doerfler excited by gene-editing licence deal

Last updated: 03:21 15 Mar 2017 AEDT, First published: 23:21 14 Mar 2017 AEDT

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”

Doug Doerfler, chief executive of MaxCyte, runs through the firm's first commercial licence deal in the gene-editing space.
Under the deal, CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.
CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.
"It's a very exciting time for the company and it's really a pleasure to be working with this advanced group that’s working in the area of inherited blood disorders," said Doerfler.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

9 hours, 27 minutes ago